For years activated natural killer (A-NK) cells have been explored with respect to their efficacy in anticancer therapy, but except for some anecdotal reports no clear clinical benefit has been shown. However, as the understanding about the interactions of NK cells and tumor cells advance, the use of A-NK cells might be revisited with more sophisticated approaches. The recent discovery of specific receptors on NK cells that interact with HLA molecules on target cells but also the discovery of specific activating receptors have allowed NK cells to step out of the shadow of T cells to be considered for cellular therapy of malignant diseases. NK cells are a subgroup of lymphoid cells that provide one of the first lines of defense against virus-infected and tumor cells. For clinical use NK cells have to be enriched to deplete contaminating T lymphocytes which is especially important in allogeneic NK cell infusion. Recently attention has been drawn to the clonal NK cell line NK-92, which appears as an attractive alternative for the adoptive immunotherapy of malignancies. NK-92 exhibits high cytotoxicity towards a broad range of tumors, which can be further extended by the recombinant expression of chimeric antigen receptors. This review summarizes the key features of primary and clonal NK cells and their potential use in adoptive immunotherapy of malignancies. 
Pre-Requisites for Natural Killer Cells to Lyse Malignant Targets
The occurrence and progression of cancer is linked to a failure of the patients immune response to eradicate tumor cells. Mechanisms allowing tumor cells to escape immunosurveillance by natural killer (NK) and other immune cells may play a major role in tumor progression [1] [2] [3] . NK cells are a subgroup of lymphoid cells that provide one of the first lines of defense against virus-infected and tumor cells. They do not rearrange their immune receptor genes, and their cytotoxicity is not MHC-restricted. NK cells mediate spontaneous killing of various tumor cells without prior sensitization. NK cells kill target cells predominantly through release of perforin, which causes target cell permeability followed by DNA disintegration and cell death mediated by esterases such as granzyme B. In addition to direct cytolytic/apoptotic effects mediated by the granzyme/perforin system, some target cell killing occurs through molecules of the TNF superfamily such as Fas/FasL, TRAIL, TWEAK and TNF-α. Activity of NK cells towards their malignant targets depends on several parameters, including binding of the respective target cell by cell adhesion molecules (CAMs); regulation of NK cell function orchestrated by an array of activating and inhibitory NK cell receptors (NKRs) and/or the sensitivity of target cells towards cytolytic effectors (perforin, granzyme, Fas-L). Cell-cell contact between NK cells and their target cells is a prerequisite for killing of target cells, and prevention of binding ultimately leads to tumor cell resistance [4] . Attachment of NK cells to target cells initially utilizes CAMs [5] . In addition, CAMs subsequently provide stimulatory signals for the activation of effector cells [4] . The LFA-1/ICAM-1 ligand/receptor pair serves as a dominant adhesion pathway for NK cells. Upon activation the binding affinity of LFA-1 for ICAM-1, and to a lesser extent ICAM-2 and ICAM-3, is rapidly increased. After binding to its target cell, NK cell activation is further regulated by a balance of signals that are generated from inhibitory and activating receptors [6] [7] [8] [9] . MHC class I molecules function as major ligands for a wide array of inhibitory receptors clonally expressed on NK cells. While this mechanism might prevent self-destruction under physiological conditions, up-regulation of certain HLA alleles may allow malignant cells to escape NK cell immunosurveillance. For example, expression of HLA-G, a ligand for KIR2DL4, was reported to protect otherwise susceptible target cells from NK cell lysis [10] [11] [12] [13] . In contrast, a mismatch of HLA-C in haploidentical stem cell transplantation (HSCT) results in long-term remission, attributed to a graft-versus-leukemia (GVL) activity of NK cells arising from the transplant [14] . Tumor cells may also evade cytotoxic effector function of NK cells by resistance to perforin/granzyme B-mediated lysis and the induction of apoptosis by utilization of members of the TNF receptor family (Fas, TNF, TRAIL) [15, 16] . Perforin, as a pore-forming protein, binds to the target cell membrane, leading to loss of osmotic stability and influx of granule-associated proteins that are able to induce apoptosis [17] . The binding ability of perforin to leukemic blasts has been reported to correlate with their sensitivity towards NK cell cytotoxicity. Abundant perforin binding results in sensitive targets, whereas reduced binding of perforin was observed in resistant cells [17, 18] .
Natural Killer Cells in Cancer Therapy
Sensitization of NK cells is not prerequisite for cytotoxic activity, which on the other hand is enhanced upon activation of NK cells with a variety of cytokines [19, 20] . These activated NK (A-NK) cells, typically expanded from the peripheral blood and, activated by IL-2, are sometimes also referred to as lymphokine-activated killer (LAK) cells, although the majority (>90%) of IL-2-activated blood mononuclear cells represent polyclonal T cells. Recently the term A-NK cells has been introduced due to the fact that adherence and activation is necessary to expand highly lytic NK cells and that an increasing number of different cytokines is reported to activate NK cells [21] . In patients with malignant disorders, NK cell function has been shown to be impaired in terms of a reduced in vitro proliferative response and reduced cytotoxic activity [22, review in 23] . Although dysfunctions in NK cell populations might allow the occurrence and metastasis of tumor cells in these patients [23] , there is also evidence that tumor cells themselves may have developed mechanisms to escape NK cell immunosurveillance e.g. by up-regulation of classical (HLA-A,B,C) and nonclassical (HLA-G,E) human lymphocyte antigens (HLA) [24, 25] . These HLA alleles are able to inhibit NK cell function upon ligation with certain killer cell immunoglobulin like receptors (KIRs) on effector cells such as NK cells [26] . Inhibitory NK cell receptors Numerous studies have been conducted and are still ongoing, aiming at improving the antitumor effect of NK cells by either endogenous activation of the patients' own NK cells through administration of cytokines [27] [28] [29] [30] or through adoptive use of ex vivo expanded autologous [31] [32] [33] or donor-derived [34, 35] A-NK or LAK cells, or a combination thereof [31, 32, 36] . The safety and efficacy of adoptive A-NK cell therapy has been examined in solid [32] [33] [34] 36] tumors as well as in hematological malignancies [31, 37] where NK cells are used in combination with high-dose chemotherapy to promote the GVL effect without inducing the potentially lethal graft-versus-host reaction which is largely mediated by T cells. While the systemic application of IL-2 has proved to be less well tolerated in doses necessary to achieve relevant concentrations at the site of the tumor [36] , the repeated intravenous transfusion of up to 10 11 A-NK cells in some trials was well tolerated and did not lead to adverse reactions [34] . However, only few patients could benefit from these treatments thus far [23] .
Natural Killer Cells and Stem Cell Transplantation
Recent observations suggest that the ability of leukemia cells to escape immunosurveillance involving NK cells may contribute to the poor outcome of the disease. In HLA-C-mismatched transplantation graft-mediated NK cell cytotoxicity against host leukemia cells in the absence of KIR ligands has been shown to induce long-lasting remission in acute myelocytic leukemia (AML) patients [14] . In contrast, KIR mismatch did not translate into improvement of disease-free survival in acute lymphatic leukemia (ALL), suggesting that ALL blasts exhibit mechanisms of resistance other than -or in addition to -the involvement of KIRs. In NK cell-sensitive leukemias, such as AML, the adoptive immunotherapy using NK cells may therefore promise to induce potent antileukemic effects. Several trials are currently underway to analyze the safety and efficacy of adoptively transfused donor NK cells. Especially in the setting of HSCT from haploidentical donors -where donor lymphocytes can not be used -the adoptive transfer of immunomagnetically purified and CD3-negative NK cells is analyzed with respect to safety and efficacy [38] . It remains to be seen if the beneficial outcome that was retrospectively observed in transplanted patients with a KIR mismatch in graft direction will eventually translate into clinical protocols involving NK-based cell therapies.
Clonal Natural Killer Cell Lines for the Immunotherapy of Malignancies
To date, only few NK cell lines could be established from patients with large granular lymphoma [review in 39], and although some of them were shown to have maintained cytotoxicity, they differ considerably with regard to the in vitro tumoricidal properties [39, 40] . 
Retargeting of Cytolytic Effector Cells
Endowing cytolytic effector cells with chimeric antigen receptors was initially developed as a strategy to circumvent the dependence on professional antigen-presenting cells for activation of naïve T cells and bypass MHC-restricted recognition of peptide antigens on target cells as requirement for the initiation of cytolytic effector functions [reviews in 43, 44] . This might help to overcome some of the limitations inherent to adoptive transfer of tumor-infiltrating lymphocytes or lymphokine-activated killer cells such as heterogeneity of effector cell populations and poorly defined target specificity while the principal advantages of a cell-based therapy, i.e. the high intrinsic cytotoxic potential of the effector cells and their capacity to extravasate and home to tumor sites, could be retained. Specificity of chimeric antigen receptors is provided by the incorporation of heterologous binding domains derived from natural ligands or antibodies for direct, MHC-independent recognition of antigens expressed on the surface of target cells. The binding domains are genetically fused to effector molecules derived from proteins that are naturally involved in T-cell signaling such as the T-cell receptor (TCR) alpha and beta chains [45] , or components of the TCR-associated CD3 complex [43, 44] . Upon antigen binding the chimeric receptors link to endogenous signaling pathways and generate activating signals similar to those initiated by the TCR complex. An important improvement in the design of chimeric antigen receptors was to combine antigen recognition and signaling capability in a single chain configuration. For the construction of such chimeric antigen receptors recombinant single chain Fv (scFv) antibody fragments were genetically fused to different receptor subunits that serve as signaling molecules in lymphocytes. The identification of suitable target antigens on tumor cells is an important prerequisite for such approaches to be successful. Chimeric antigen receptors with specificity for the pancarcinoma antigen TAG-72 expressed by most human adenocarcinomas [46] and carcinoembryonic antigen [47] ed at the cell surface and as important signaling molecules allow a cell to respond to extracellular peptide growth factors [48] . Epithelial cells of most organs including normal ovarian epithelium express ErbB2/Her2 at relatively low levels. These levels are substantially elevated in several types of carcinomas. Elevated levels of EGFR and ErbB2/HER2 have been shown to directly contribute to malignancy.
NK-92 Cells Genetically Engineered to Recognize Tumor Antigens
We have enhanced the antitumoral activity of NK-92 cells and expanded the range of tumor entities suitable for NK-92-based therapies by generating genetically modified NK-92 cells (NK-92-scFv(FRP5)-zeta) that express a chimeric antigen receptor specific for the tumor-associated ErbB2/HER2 antigen [49] . The chimeric antigen receptor consists of a recombinant scFv antibody fragment derived from the ErbB2/HER2-specific antibody FRP5 [56], a flexible hinge region derived form CD8 alpha, and transmembrane and intracellular regions of the CD3 zeta chain ( fig. 1 ).
Modified NK-92-scFv(FRP5)-zeta cells retain the ability of parental NK-92 cells to efficiently lyse malignant cells of hematologic origin, but in addition are now highly active also against cancer cells of epithelial origin. In our recent study 6 out of 7 established tumor cell lines and primary cancer cells originating from human breast as well as ovarian and squamous cell carcinomas, and expressing elevated levels of receptor tyrosine kinases such as ErbB2/HER2 or EGFR were completely resistant to NK-92 mediated lysis, with the remaining cell line being only weakly sensitive [49] . In contrast, all of the ErbB2/HER2-overexpressing, NK-92-resistant cells and cell lines were efficiently lysed by NK-92-scFv(FRP5)-zeta cells. These results indicate that grafted recognition of tumor antigens by NK-92 cells is capable to overcome tumor cell resistance. Currently we are working to broaden the specificity of NK-92 cells towards otherwise resistant hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) by grafting NK-92 cells with CD19 scFv [50] .
Conclusion and Outlook
As with other cellular immunotherapies ( fig. 2) , the tumor burden seems to be critical for the clinical outcome of adoptive therapies with NK cells. However, based on the safety data obtained with recent clinical studies employing highly enriched, T-cell-depleted NK cells or clonal NK cell lines, adoptive immunotherapy of malignancies with NK cells should be viewed as part of a comprehensive cancer treatment approach that may include conventional and experimental therapies. With better insight into the mechanisms by which NK cells mature, the function of different NK cell subsets, and the cross-talk of these cells with dendritic cells and T lymphocytes, more rational approaches in adoptive immunotherapy against primary tumors and their metastases will eventually be possible.
